A new analysis of 20 years of data contradicts previously published claims that United States pharmaceutical companies are better innovators than their European counterparts, and questions whether Americans actually benefit from the higher prices they pay for many prescription medications. The re-analysis by Donald W. Light, PhD, a professor of social medicine and comparative health systems at the UMDNJ-School of Osteopathic medicine, appears in the current Health Affairs-web exclusive.
Copyright ArthritisInsight.com